PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34643108-10	2022	For LR-3 observations, progression to LR-4 was 22.2% (95% CI 9.6%-43.8%) and LR-5 was 11.1% (95% CI 3.0%-28.4%) for both readers.	Lawrencium	38-40	LDL receptor related protein 5	Homo sapiens	4-8	
35445513-6	2022	For LR-4 observations, the 1-year, 3-year, and 5-year cumulative incidences of progression to a malignant category were 18.5% (95% confidence interval, 6.6-35.2%), 43.0% (23.1-61.5%), and 52.5% (25.9-73.5%), which were significantly higher than those of LR-2 and LR-3 (P<0.001).	Lawrencium	4-6	LDL receptor related protein 5	Homo sapiens	263-267	
35445513-7	2022	For LR-3, the 1-year, 3-year, and 5-year cumulative incidences of progression to LR-4 or higher were 4.1% (1.1-10.4%), 13.9% (6.7-23.6%), and 23.1% (12.7-35.4%), which were significantly higher than that of LR-2 (P=0.009).	Lawrencium	81-83	LDL receptor related protein 5	Homo sapiens	4-8	
35445513-7	2022	For LR-3, the 1-year, 3-year, and 5-year cumulative incidences of progression to LR-4 or higher were 4.1% (1.1-10.4%), 13.9% (6.7-23.6%), and 23.1% (12.7-35.4%), which were significantly higher than that of LR-2 (P=0.009).	Lawrencium	207-209	LDL receptor related protein 5	Homo sapiens	4-8